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Devices, Drugs, and the Food and Drug Administration
Increasing Implications for Ischemic Stroke
Anthony J. Furlan, MD; Marc Fisher, MD
The approval process at the Center for Devices andRadiological Health (CDRH) of the Food and Drug
Administration (FDA) has been of little interest previously to
stroke neurologists, but an increasing number of devices are
being approved for stroke prevention (carotid stents, patent
foramen ovale closure) and now also for acute ischemic
stroke intervention. Felten et al provide a review of the
CDRH approval process and give their perspective concern-
ing the recent approval of the Concentric Merci Retriever in
acute ischemic stroke. Drs Becker and Brott were members of
the FDA advisory panel that reviewed the MERCI (Mechan-
ical Embolus Removal in Cerebral Ischemia) Trial and
approval application. Despite concerns raised by the advisory
panel, the Merci device was ultimately approved by CDRH.
It is not our purpose to arbitrate the specific concerns raised
by the advisory panel or to question the CDRH decision;
readers can judge the strength of the evidence for themselves.
However, we do wish to consider some of the implications of
this decision for patient care and stroke clinical research.
The Merci Retriever was approved for clot removal in
brain arteries and not as a therapeutic modality for acute
ischemic stroke. This distinction is critically important. The
MERCI Trial relied on historical controls (mostly data from
PRolyse in Acute Cerebral Thromboembolism [PROACT] II)
for demonstration of safety, recanalization efficacy, and
clinical outcome.1 Although not the primary end point, it is
useful to summarize clinical outcomes in the MERCI Trial.
The median baseline National Institutes of Health (NIH)
Stroke Scale score was 17 in the PROACT II controls and 19
in the MERCI patients, implying that the MERCI patients had
more severe strokes. This could partly reflect the inclusion of
patients with internal carotid and vertebral basilar occlusions
in MERCI. The overall 90-day favorable outcome in MERCI,
defined as a modified Rankin score of 2, was 31%, which
is not significantly better than the rate in the middle cerebral
artery controls in PROACT II (25%). In patients who recana-
lized, the favorable outcome was 53%. The 24-hour symp-
tomatic brain hemorrhage rate was 8%, very similar to the
10% rate in PROACT II, in which patients received intra-ar-
terial (IA) prourokinase. The 90-day mortality rate was 27%
in the PROACT II controls and 40% in the MERCI Trial. The
conclusions we draw from MERCI are that despite the 54%
partial or complete immediate recanalization rate (63% at 1
hour in PROACT II), there was no overall evidence of
improved patient outcome at 90 days. There was a suggestion
of improved outcome in patients who recanalized. The
symptomatic brain hemorrhage rate was similar to patients
given an IA thrombolytic agent, and the 90-day mortality was
higher in the MERCI trial.
Although these results could reflect case mix and insuffi-
cient sample size, it also reinforces that safely re-establishing
brain reperfusion alone does not guarantee meaningful clin-
ical improvement in patients with acute stroke. Additionally
establishment of clinical efficacy for reperfusion therapy
beyond 3 hours from stroke onset with either device, drug or
both, will require a randomized, controlled trial stratified by
stroke severity and site of occlusion that also includes
patients still capable of responding to reperfusion therapy (ie,
patients with ischemic but still salvageable tissue, the ische-
mic penumbra). Reperfusing irreversibly injured brain tissue
will not improve outcome and may lead to an increased risk
of hemorrhage. If the Merci Retriever can be used in
conjunction with advanced imaging technology that can
identify the ischemic penumbra, then it is possible that
clinical efficacy could be established beyond 3 hours. Such a
trial, Magnetic Resonance and REcanalization of Stroke Clots
Using Embolectomy (MR RESCUE), is ongoing, and it will
be interesting to see how rapidly patient recruitment occurs.
The approval of the Concentric Merci Retriever for use in
ischemic stroke highlights important differences in the FDA
approval process between CDRH and the Center for Drug
Evaluation and Research (CDER) and the Center for Biolog-
ics Evaluation and Research (CBER). Although the 3 pillars
of approval are safety, mechanism of action, and clinical
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efficacy, each FDA center weighs these quite differently.
Concerns about the FDA device approval process were first
raised by the Temple Report of 1993.2 The Temple Report
recommended that the principles of sound clinical trial
design, including appropriate controls, statistical design, data
management, and end points, should be applied to devices as
well as drugs. However, notably, the Temple Report also
stated that “randomized trials are not a routine requirement
but will often prove practical and desirable.” Furthermore,
“assuming there are no other choices and that the natural
history of patients getting the device is known to be dismal,
so that no treatment or placebo is not an acceptable treatment,
any (device) study would of necessity be a single arm
historically controlled trial.” After the Temple Report, the
FDA introduced changes that brought device approval more
in parallel with drug approval. However, when this resulted in
delays in device approval unacceptable to industry, Congress
passed the FDA Modernization Act (FDAMA) in 1997.3
FDAMA included language requiring the FDA to consider
“the least burdensome means” when approving the marketing
of a new device. This often does not include a randomized
controlled clinical efficacy trial, even for the more rigorous
premarketing assessment application. Although CDRH
adopted the “least burdensome” FDAMA mandate,4 neither
CDER nor CBER has approved pharmacological agents
based only on historical controls and without clinical efficacy
being demonstrated in randomized controlled trials. The key
reason for this difference is that device approval typically is
based on a mechanistic (“tool”) end point (eg, thrombus
removal, closing a hole, reducing a stenosis), whereas drug
approval has required the much tougher end point of clinical
efficacy based on randomized trials.
The negative implications of the CDRH device approval
process for randomized clinical efficacy trials have been
increasingly recognized.5 After a device is approved by
CDRH, interventionalists are often reluctant to randomize to
a medical control arm in a clinical trial. Off label use of
approved devices has been especially recognized by the FDA
as a major impediment to the conduct of randomized clinical
efficacy trials.5 Although the reluctance of interventionalists
to participate in randomized clinical trials may have some
ethical basis, reimbursement for a CDRH-approved device by
the Center for Medicaid and Medicare Services (CMS)
provides a powerful financial disincentive to the participation
in or the performance of randomized clinical efficacy trials.5
The traditional FDA arguments for reviewing devices
differently from drugs are summarized by Felten et al.
However, there are circumstances in which such distinctions
become artificial. To use the current example, the distinction
between a device and a pharmacological agent such as tissue
plasminogen activator or prourokinase becomes blurred when
the criterion is simply safe and effective clot removal in brain
arteries. Ironically, although there is no demonstrated differ-
ence in either recanalization efficacy or safety between the
Merci Retriever and pro-urokinase, and the prourokinase data
are based on randomized controlled trials rather than histor-
ical controls, the FDA approval process has resulted in
approval of a device for this purpose but not the drug.
We suggest that CBER and CDER should consider a “least
burdensome” mechanistic approval option for pharmacological
agents similar to the CDHR process for devices (eg, approving a
thrombolytic agent based on demonstrated safe and effective recan-
alization). This important emerging issue was addressed recently by
an FDA advisory panel on the design of clinical trials for endovas-
cular devices to treat and prevent acute ischemic stroke and the
Stroke Therapy Academic Industry Roundtable (STAIR) IV con-
ference.6,7 We also suggest that “mechanistic approval” of either a
device or a drug should be provisional and lead to only limited
reimbursement by CMS. Full reimbursement by CMS for a device,
just as for a drug, should be linked to unequivocal demonstration of
clinical efficacy. Furthermore, in our opinion, there is no justifica-
tion for CDRH, CDER, and CBER to grant approval using differing
standards of clinical efficacy.8 The highest level of evidence for
clinical efficacy for a device or a drug remains a randomized,
controlled, adequately powered clinical trial. Less strict alternatives,
such as historical controls, objective performance criteria, and
validated surrogate end points, should be considered by CDRH,
CDER, and CBER, but the circumstances under which such
alternatives might be acceptable for approval should be standard-
ized across FDA centers.
Although NIH, CDRH, and CMS have collaborated in
studies such as Carotid Revascularization Endarterectomy
Versus Stent Trial to fulfill premarket reimbursement and to
provide proof of clinical efficacy requirements, such collab-
oration remains the exception rather than the rule with
devices. We suggest that the path to approval at CDER and
CBER may be too inflexible and may discourage pharmaceu-
tical participation in stroke research. We believe that the
evolution of new stroke therapies requires a similar evolution
in the FDA device and drug approval process. A more
homogeneous and consistent approach across FDA centers
would help advance the care of patients with stroke and other
serious and life-threatening conditions.
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